Internal Server Error

Cantargia - About the company

Cantargia is a public company based in Lund (Sweden), founded in 2010. It operates as a Developer of antibody-based therapy for the treatment of solid tumors and cancers. Cantargia has raised $1M in funding. The company has 3460 active competitors, including 1140 funded and 795 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Kite Pharma.

Company Details

Developer of antibody-based therapy for the treatment of solid tumors and cancers. The company's lead product candidate CAN04, to block cancer cell signaling via the interleukin-1 system, which among other things can limit the inflammatory tumor uses for growth and defense strategy. CAN04 also stimulates the body's immune system to eliminate cancer cells.
Key Metrics
Founded Year
2010
Location
Lund, Sweden
Stage
Public
Total Funding
$1M in 3 rounds
Latest Funding Round
Ranked
Employee Count
31 as on Sep 30, 2026
Similar Companies
Exit Details
Public

Cantargia's IPO details

Cantargia got listed on Mar 17, 2015.
Click here to take a look at Cantargia's IPO in detail
Sign up to download Cantargia's company profile

Cantargia's funding and investors

Cantargia has raised a total funding of $1M over 3 rounds. Its first funding round was on Jul 05, 2013. Cantargia has 11 institutional investors.

Here is the list of recent funding rounds of Cantargia:
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Dec 15, 2020
2368732
Post IPO
9958765
7857359
4042039
9659844
Feb 19, 2020
6155606
Post IPO
2299062
4561689
4767925
Jul 05, 2013
7321532
PE
9086746
8045271
9139335
lockAccess funding benchmarks and valuations. Sign up today!

Cantargia's founders and board of directors

Founder? Claim Profile

Cantargia's employee count trend

Cantargia has 31 employees as of Sep 26. Here is Cantargia's employee count trend over the years:
Employee count trend for Cantargia
lockUncover Cantargia's growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

Cantargia's Competitors and alternates

Top competitors of Cantargia include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of Cantargia, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for Jazz Pharmaceuticals
Jazz Pharmaceuticals
2003, Dublin (Ireland), Public
Developer of novel biopharmaceutical medicines for unmet medical needs
$265M
82/100
2nd
Logo for BeiGene
BeiGene
2010, Cambridge (United States), Public
Developer of targeted and immune-oncology drugs against cancer
$172M
77/100
3rd
Logo for Kite Pharma
Kite Pharma
2009, Los Angeles (United States), Acquired
Developer of cancer immunotherapy products using genetic engineering
$97.7M
76/100
4th
Logo for Attovia
Attovia
2023, Fremont (United States), Public
Developer of antibody-based therapeutics for immune-mediated diseases and oncology
$255M
72/100
5th
Logo for Tango Therapeutics
Tango Therapeutics
2017, Cambridge (United States), Public
Developer of drugs for the treatment of cancer
$165M
72/100
6th
Logo for Elicio
Elicio
2012, Cambridge (United States), Public
Developer of vaccines for treating cancer
$47.4M
72/100
7th
Logo for Immuneel
Immuneel
2018, Bengaluru (India), Series B
Developer of T-cell therapies for the treatment of cancer
$49.8M
71/100
8th
Logo for BioNTech
BioNTech
2008, Mainz (Germany), Public
Developer of immunotherapeutics for the treatment of cancer and other diseases
$861M
71/100
9th
Logo for Erasca
Erasca
2018, San Diego (United States), Public
Developer of small molecule based therapeutics for cancer
$300M
71/100
10th
Logo for Strand Therapeutics
Strand Therapeutics
2017, Cambridge (United States), Series B
Provider of platform to deliver mRNA therapeutics for multi functional treatments
$256M
71/100
491st
Logo for Cantargia
Cantargia
2010, Lund (Sweden), Public
Developer of antibody-based therapy for the treatment of solid tumors and cancers
$1M
52/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on Cantargia's competitors? Click here to see the top ones

Cantargia's Investments and acquisitions

Cantargia has made no investments or acquisitions yet.

Reports related to Cantargia

Here is the latest report on Cantargia's sector:

News related to Cantargia

lockFilter this list
Media has covered Cantargia for a total of 12 events in the last 1 year, 6 of them have been about company updates and 1 about people movement.
•
Cantargia Appoints Dr. Monic Stuart as Chief Medical OfficerAccess Newswire•Oct 26, 2026•Cantargia
•
Cantargia Publishes Half-Year Report 2026Access Newswire•Aug 19, 2026•Cantargia
•
Cantargia Announces Changes in Number of Shares and VotesAccess Newswire•Jul 31, 2026•Cantargia
•
•
Cantargia Publishes Full Year Report 2025Access Newswire•Feb 20, 2026•Cantargia
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about Cantargia

Explore our recently published companies
  • Convello - Valsad based, 1998 founded, Unfunded company
  • Akshat Green - Patna based, 2025 founded, Unfunded company
  • Xunoia - Hyderabad based, 2025 founded, Unfunded company
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford